N@N

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY), Down By 7.80% ($0.91) From $11.670 After BUYINS.NET Report Predicted Weakness After

^{Published on 2012-05-02 07:41:06 - WOPRAI}
 

May 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, April 30th 2012 stating that ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=alny&id=269400

At the time this story was written, ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) is Down By 7.80% ($0.91) From $11.670 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Its lead RNAi therapeutic program includes ALN-RSV01, which is in Phase II clinical trial for the treatment of human respiratory syncytial virus (RSV) infection. The companys product pipeline also comprises ALN-VSP, a Phase I clinical trial product to treat liver cancers. Its products under development stage include ALN-RSV02 for the treatment of RSV infection; ALN TTR01 and ALN TTR02 to treat TTR-Mediated Amyloidosis; ALN-PCS for the treatment of PCSK9/Hypercholesterolemia; and ALN-HTT to treat Huntingtons disease. It has license and collaboration agreements with Roche to develop and commercialize therapeutic products that function through RNAi; Takeda for the development and commercialization of RNAi therapeutics; and with Medtronic Inc. and CHDI Foundation, Inc. to advance ALN-HTT, a novel drug-device combination for the treatment of Huntington's disease. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net